Hepatocellular Carcinoma Surveillance
|
|
- Marilyn Taylor
- 5 years ago
- Views:
Transcription
1 Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1
2 Patient Case 69 year-old otherwise healthy male with compensated HCV-related cirrhosis Treated with PEG-IFN and RBV in 2011 and achieved SVR Continues to feel well with no cirrhosis-related complications Normal ultrasound and AFP every 6 months for past 5 years Patient asks if he needs to continue HCC surveillance 2016 AMERICAN ASSOCIATION 309 FOR THE STUDY OF LIVER DISEASES 2
3 Key Questions What is the risk of HCC in patients who achieve SVR? Is continued HCC surveillance indicated in this patient? If so, what is the optimal HCC surveillance strategy? 2016 AMERICAN ASSOCIATION 310 FOR THE STUDY OF LIVER DISEASES 3
4 Key Questions What is the risk of HCC in patients who achieve SVR? Is continued HCC surveillance indicated in this patient? If so, what is the optimal HCC surveillance strategy? 2016 AMERICAN ASSOCIATION 311 FOR THE STUDY OF LIVER DISEASES 4
5 Patients with HCV cirrhosis are at risk for HCC 2016 AMERICAN ASSOCIATION 312 FOR THE STUDY OF LIVER DISEASES 5 Niedarau et al. Hepatology 1998 Degos et al. Gut 2000
6 SVR is associated with reduced risk of HCC 2016 AMERICAN ASSOCIATION 313 FOR THE STUDY OF LIVER DISEASES 6 Morgan et al. Ann Intern Med 2013
7 However, HCC risk persists in patients post SVR 2016 AMERICAN ASSOCIATION 314 FOR THE STUDY OF LIVER DISEASES 7 Kobayashi et al. Liver Int 2007
8 Risk factors for HCC Development among SVR Patients Study SVR Patients with Cirrhosis Median Follow-up # Incident HCC Risk Factors Van der Meer (84%) 6.7 years 50 (5%) Age Chang (38.9%) 3.5 years 37 (4.2%) Arase (7.8%) 8.1 years 44 (2.3%) Age, F3-F4, AFP, thrombocytopenia Male, age, alcohol, diabetes Huang (13.4%) 4.4 years 33 (5.1%) Age, F4 stage, GGT 2016 AMERICAN ASSOCIATION 315 FOR THE STUDY OF LIVER DISEASES 8
9 Risk persists for > 10 years after SVR despite potential fibrosis regression Case No Years after HCV treatment Histology 1 18 F F F F3 5 > 10 years F AMERICAN ASSOCIATION 316 FOR THE STUDY OF LIVER DISEASES 9 Nojiri et al. Oncol Lett 2010
10 SVR associated with with reduced risk of HCC but risk may plateau >7 years post SVR 2016 AMERICAN ASSOCIATION 317 FOR THE STUDY OF LIVER DISEASES 10 Van der Meer et al JAMA 2012
11 Key Question What is the risk of HCC in patients who achieve SVR and is continued HCC surveillance indicated? SVR reduces HCC risk, but patients remain at elevated risk (annual incidence 0.5 2%) so surveillance indicated HCC risk prolonged (> 10 years) so surveillance may be be needed indefinitely HCC risk appears to plateau after first 6-7 years but unknown when falls below cost effectiveness threshold 2016 AMERICAN ASSOCIATION 318 FOR THE STUDY OF LIVER DISEASES 11
12 Follow-up Question Does age matter? Is HCC surveillance indicated in this 69-year old patient? 2016 AMERICAN ASSOCIATION 319 FOR THE STUDY OF LIVER DISEASES 12
13 Should surveillance be continued in the elderly? Systematic review of HCC outcomes in elderly patients Despite higher risk of non-liver related mortality, elderly patients had similar survival as non-elderly HCC patients Confounders: Higher comorbidity, worse performance status, provider reluctance to aggressively treat, smaller tumor burden, and less advanced fibrosis Conclusion: Prognosis driven more by tumor burden, liver function, and performance status than age 2016 AMERICAN ASSOCIATION 320 FOR THE STUDY OF LIVER DISEASES 13 Borzio et al. World J Gastro 2015
14 Follow-up Question Is continued HCC surveillance indicated in this 69- year old patient? No absolute age cut-off at which HCC surveillance should be routinely discontinued Personalized decision based on comorbidities, performance status, degree of liver dysfunction, and patient/provider willingness to undergo HCC-directed treatment if needed 2016 AMERICAN ASSOCIATION 321 FOR THE STUDY OF LIVER DISEASES 14
15 Follow-up Question Does this recommendation change with new DAA agents compared to IFN-based treatments? 2016 AMERICAN ASSOCIATION 322 FOR THE STUDY OF LIVER DISEASES 15
16 HCC risk likely persists in patients post SVR with new DAA agents Proportion of patients without HCC DAA-treated patients IFN-treated historic controls Time (years) 2016 AMERICAN ASSOCIATION 323 FOR THE STUDY OF LIVER DISEASES 16 Kozbial et al. J Hepatology 2016
17 HCC risk persists in patients post SVR 366 patients with cirrhosis and treated with DAAs 285 without HCC history 59 with history of HCC 9 (3.2%) with HCC within 6 months 2016 AMERICAN ASSOCIATION 324 FOR THE STUDY OF LIVER DISEASES 17 Conti et al. J Hepatology 2016
18 Recurrence of HCC may increase post SVR 366 patients with cirrhosis and treated with DAAs 285 without HCC history 59 with history of HCC 17 (28.3%) with HCC recurrence within 6 months 2016 AMERICAN ASSOCIATION 325 FOR THE STUDY OF LIVER DISEASES 18 Conti et al. J Hepatology 2016
19 Recurrence of HCC may increase post SVR o 58 HCC patients from 4 centers in Spain who had complete response after resection, ablation, or TACE All underwent DAA therapy after complete response o Recurrence occurred in 16 (27.6%) Median time from HCC treatment to DAA treatment was 11.2 ( ) months Median time from DAA treatment to HCC recurrence was 3.5 (1.1 8) months o Subgroup analysis: 41.2% recurrence if started DAA < 4 months of complete response vs. 21.9% if started > 4 months after complete response 2016 AMERICAN ASSOCIATION FOR THE 326 STUDY OF LIVER DISEASES 19
20 Follow-up Question Does this recommendation change with new DAA agents compared to IFN-based treatments? HCC risk likely remains high post SVR with new DAA agents so continued surveillance is indicated Further data are needed to enumerate HCC risk among DAA-treated patients May be higher given HCV therapy can be delivered to patients with more advanced liver dysfunction 2016 AMERICAN ASSOCIATION 327 FOR THE STUDY OF LIVER DISEASES 20
21 Key Question What is the optimal HCC surveillance strategy in this patient? 2016 AMERICAN ASSOCIATION 328 FOR THE STUDY OF LIVER DISEASES 21
22 HCC surveillance associated with improved survival in patients with cirrhosis Author Lead Time Survival Rates Significance El-Serag 2011 Tong 2010 Wong 2008 Tanaka 2006 Trevisani days 118 days 236 days 238 days days Median survival 298 vs. 130 days 3-year survival 62.5% vs. 36.6% 2-year survival 49.4% vs. 28.6% Median survival 6.3 vs. 5.3 years Median survival 30 vs. 20 months OR 0.81 (95%CI ) p=0.007 p=0.035 p=0.016 p< AMERICAN ASSOCIATION 329 FOR THE STUDY OF LIVER DISEASES 22 Singal et al. PLOS Medicine 2014
23 Ultrasound is efficacious for HCC surveillance 2016 AMERICAN ASSOCIATION 330 FOR THE STUDY OF LIVER DISEASES 23 Singal et al. Aliment Pharm Ther 2009
24 Efficacious may not equal effective Efficacy Access Recommend Adherence Effectivenes s Therapy A 50% 90% 90% 90% 37% Therapy B 90% 80% 60% 50% 22% 2016 AMERICAN ASSOCIATION 331 FOR THE STUDY OF LIVER DISEASES 24 El Serag et al. Hepatology 2010
25 Ultrasound is not as effective in clinical practice Surveillance Test Sensitivity Sensitivity Early Stage Specificity AFP alone 27/41 (65.9%) 19/41 (46.3%) 363/401 (90.5%) Ultrasound alone 18/41* (43.9%) 13/41 (31.7%) 367/401 (91.5%) 2016 AMERICAN ASSOCIATION 332 FOR THE STUDY OF LIVER DISEASES 25 Singal et al Cancer Epi Biomark Prev 2012
26 Potential limitations of Ultrasound Operator characteristics Variable experience and training of ultrasound technicians Patient characteristics Obesity Liver nodularity and echogenicity Presence of ascites 2016 AMERICAN ASSOCIATION 333 FOR THE STUDY OF LIVER DISEASES 26
27 Limitations of Ultrasound Sensitivity Retrospective cohort of 1170 ITA.LI.CA database patients Ultrasound failure in 28.9% of patients Decreased from 33% in to 26% in Variable Multivariate analysis Annual vs. semiannual 2.20 ( ) Child Pugh B 1.60 ( ) Alpha fetoprotein (AFP)* 1.00 ( ) * Marker of aggressive tumor biology 2016 AMERICAN ASSOCIATION 334 FOR THE STUDY OF LIVER DISEASES 27 Del Poggio et al. Clin Gastro Hep 2014
28 Limitations of Ultrasound Quality Retrospective cohort study of 941 patients with cirrhosis Ultrasound inadequate quality for surveillance in 134 (20.3%) patients Variable Multivariate analysis Male gender 1.68 ( ) Child B or C cirrhosis 1.93 ( ) BMI category (BMI < 25 reference) Overweight (BMI ) Obesity class I (BMI ) Obesity class II (BMI ) Obesity class III (BMI 40) Etiology (HCV reference) Hepatitis B Alcohol-related NASH 2.29 ( ) 2.95 ( ) 6.37 ( ) 8.22 ( ) 1.87 ( ) 2.11 ( ) 2.87 ( ) 2016 AMERICAN ASSOCIATION 335 FOR THE STUDY OF LIVER DISEASES 28 Simmons et al. Aliment Pharmacol Ther (in press)
29 Potential solutions to improve effectiveness Better imaging quality Improved ultrasound quality Contrast enhanced CT or MRI Combining with biomarkers Alpha fetoprotein (AFP) AFP-L3% and DCP Others: GP73, osteopontin, etc AMERICAN ASSOCIATION 336 FOR THE STUDY OF LIVER DISEASES 29
30 CT not recommended for HCC surveillance Variable Ultrasound (n=83) CT (n=80) p-value Number of HCC 8 (10.8%) 8 (10.0%) 0.86 Proportion BCLC A 5 (55.5%) 5 (62.5%) 0.93 HCC-related mortality 5 (6.0%) 7 (8.8%) 0.46 False positive imaging 3 (3.6%) 9 (5.6%) 0.06 Cost per HCC $17,041 $57, AMERICAN ASSOCIATION 337 FOR THE STUDY OF LIVER DISEASES 30 Pocha et al. Aliment Pharm Ther 2013
31 MRI not recommended for HCC surveillance Prospective cohort study with 407 Child A-B patients 1112 surveillance rounds over 1.5 years Ultrasound and MRI done in all patients 35 patients with total of 40 HCC nodules 26 patients had BCLC stage 0 and 8 BCLC stage A Cohort MRI US P-value Sensitivity 97% 40% P<0.001 Sensitivity for BCLC O 96% 42% P<0.001 Specificity 94% 90% P= AMERICAN ASSOCIATION 338 FOR THE STUDY OF LIVER DISEASES 31 Lim et al AASLD abstract 2014
32 Using AFP with ultrasound improves sensitivity for tumor detection in clinical practice Surveillance Test Sensitivity Specificity Ultrasound 92.0 ( ) 74.2 ( ) AFP > ( ) 93.3 ( ) Ultrasound and AFP > ( ) 68.3 ( ) Ultrasound and AFP >20 and >2* from nadir 99.2 ( ) 71.6 ( ) 2016 AMERICAN ASSOCIATION 339 FOR THE STUDY OF LIVER DISEASES 32 Chang et al Am J Gastro 2015
33 Using AFP with ultrasound improves sensitivity for early tumor detection in clinical practice Test Sensitivity Efficacy Sensitivity Early Stage Sensitivity Effectiveness Sensitivity Early Stage AFP alone 35/51 (69%) 25/51 (49%) 27/41 (65.9%) 19/41 (46.3%) Ultrasound alone Ultrasound and AFP 43/51 (84%) 32/51 (63%) 18/41 (43.9%) 13/41 (31.7%) 47/51 (92%) 35/51 (69%) 37/41 (90.2%) 26/41 (63.4%) 2016 AMERICAN ASSOCIATION 340 FOR THE STUDY OF LIVER DISEASES 33 Singal et al Cancer Epi Biomark Prev 2012
34 AFP performance varies by cirrhosis etiology Viral cirrhosis Non-viral cirrhosis N=1128; 452 HCC and 676 non-hcc Sensitivity 70.4% 69.6% Specificity 82.6% 98.0% Percent Correctly Classified 76.9% 89.4% 2016 AMERICAN ASSOCIATION 341 FOR THE STUDY OF LIVER DISEASES 34 Gopal et al Clin Gastro Hep 2014
35 AFP performance improved by adjusting for ALT 2016 AMERICAN ASSOCIATION 342 FOR THE STUDY OF LIVER DISEASES 35 El Serag et al Gastro 2014
36 Biomarkers being evaluated in phase II/III studies AFP-L3% DCP Osteopontin GP73 Squamous cell carcinoma antigen (SCCA) Circulating MiRNA Circulating tumor cells 2016 AMERICAN ASSOCIATION 343 FOR THE STUDY OF LIVER DISEASES 36
37 Key Questions What is the optimal HCC surveillance strategy? Although ultrasound can be efficacious, it may have lower effectiveness given its operator dependent nature and differences in patient characteristics There are no data supporting routine use of CT or MRI for surveillance purposes AFP can improve sensitivity for early tumor detection and a combination of ultrasound/afp may be the optimal surveillance strategy 2016 AMERICAN ASSOCIATION 344 FOR THE STUDY OF LIVER DISEASES 37
38 Summary: Patient Case 69 year-old otherwise healthy male with compensated HCV-related cirrhosis Treated with PEG-IFN and RBV in 2011 and achieved SVR Continues to feel well with no cirrhosis-related complications Normal ultrasound and AFP every 6 months for past 5 years Patient asks if he needs to continue HCC surveillance 2016 AMERICAN ASSOCIATION 345 FOR THE STUDY OF LIVER DISEASES 38
39 Summary Patients with SVR remain at elevated risk for HCC and should continue to undergo HCC surveillance indefinitely Ultrasound with AFP every 6 months appears to be the optimal surveillance strategy to maximize early HCC detection in clinical practice 2016 AMERICAN ASSOCIATION 346 FOR THE STUDY OF LIVER DISEASES 39
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationThe Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationEarly Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
Early Detection, Curative, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis Amit G. Singal 1,2,3 *, Anjana Pillai 4, Jasmin Tiro 2,3 1 Department
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationChanging epidemiology of HCC in Italy
Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationMolecular signature for management of hepatocellular carcinoma
Molecular signature for management of hepatocellular carcinoma Yujin Hoshida, MD, PhD Liver Cancer Program, Tisch Cancer Institute Division of Liver Diseases, Department of Medicine Icahn School of Medicine
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationRisk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화
Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationTitle: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
Title: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment Authors: Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationHepatitis C (HCV) Digestive Health Recognition Program
PQRS #84 Hepatitis C: Ribonucleic Acid (RNA) Effective Clinical Process NQF 0395 Testing Before Initiating Treatment Care Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis
More informationPredictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis
Alimentary Pharmacology and Therapeutics Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis O. Simmons*, D. T. Fetzer, T. Yokoo,J.A.Marrero*,A.Yopp,
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More information«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients
«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors
More informationHCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationDetection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
nature publishing group ORIGINAL CONTRIBUTIONS 1 see related editorial on page x Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationOutreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial
Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Amit G. Singal MD MS UT Southwestern Medical Center and Parkland Health & Hospital System Dallas, TX, USA 1
More informationUltrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.
Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology
More informationXVII Annual Meeting of Hepatology
XVII Annual Meeting of Hepatology Malaga 18,19 May 2018 Chronic Hepatitis C and HCC : What is new? Massimo Colombo, MD Head,Humanitas Clinical and Research Center, Rozzano, Italy. Chairman,EASL International
More informationHIV and Hepatocellular Carcinoma. Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013
HIV and Hepatocellular Carcinoma Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013 1 In theory, there is no difference between theory and practice In practice there is Chuck
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationModern liver imaging techniques - A new era in liver ultrasound
Modern liver imaging techniques - A new era in liver ultrasound Yuko Kono, M.D., Ph.D. Clinical Professor Departments of Medicine and Radiology University of California, San Diego San Diego, USA How to
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationIs exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population
Original Article Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population Padmini Krishnamurthy, Nyla Hazratjee, Dan Opris,
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationHepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
Editorial The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals Ming-Lung Yu 1,2,3, Chung-Feng
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationKey Publications For EarlyCDT Liver for lesions
Key Publications For EarlyCDT Liver for lesions Development Studies Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma. Middleton CH, Irving W, Robertson JFR, et al. PLoS ONE.
More informationA Practical Guide to Hepatitis C Management
A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationRecurrent HCV after a Pre-LTx Course of SOF/DAC:
Recurrent HCV after a Pre-LTx Course of SOF/DAC: Didier Samuel, Teresa Antonini Centre Hépato-Biliaire, Inserm Paris Sud Research Unit 1193 Hôpital Paul Brousse, Villejuif, France 3 rd Optimize Workshop,
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationScreening and Surveillance for Hepatocellular Carcinoma (HCC) Judith Feinberg, MD Project ECHO Jan. 5, 2016
Screening and Surveillance for Hepatocellular Carcinoma (HCC) Judith Feinberg, MD Project ECHO Jan. 5, 2016 Risk Factors for HCC Cirrhosis from any cause is the primary risk factor ~ 80% occur in pts with
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationBest of EASL White Nights
Best of EASL White Nights Saint Petersburg 8 June 2017 Patients with HCC and HCV:do we really need to cure HCV? Massimo Colombo, MD Center for Translational Research in Hepatology,Humanitas Hospital, Rozzano,
More informationAccepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia
More informationHCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011
HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More information